Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)
Mandate

Vinge advises Healthcap in conjunction with investment in Cortendo AB (publ)

November 03, 2014

Vinge has advised HealthCap VI L.P in connection with the execution of an investment agreement with Cortendo AB (publ) (“Cortendo”). The investment will be effected through a directed new issue of shares to HealthCap and other investors.

The new issue must be approved by a shareholders’ meeting of Cortendo and the meeting is expected to be held on or about 1 December 2014.Cortendo is a Swedish biopharmaceutical company which has its base in the United States.

Vinge’s team consisted of responsible partner Johan Winnerblad and associate Alex Miler.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026